Related Experiment Video
Updated: Mar 5, 2026
11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
39.6K
Neurotransmission systems in Parkinson's disease
Reviews in the Neurosciences
|March 23, 2017
Summary
Parkinson's disease (PD) involves α-synuclein buildup and affects motor and non-motor functions. This review examines neurotransmitter system disturbances in PD pathophysiology and potential treatments.
Area of Science:
- Neuroscience
- Neurology
- Pathophysiology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by α-synuclein accumulation (Lewy bodies).
- PD presents with motor symptoms (tremor, rigidity) and increasingly recognized non-motor symptoms (REM sleep disorder, depression, cognitive decline).
- Motor deficits often stem from synucleinopathy in the nigrostriatal pathway.
Purpose of the Study:
- To comprehensively review the role of dopaminergic and non-dopaminergic neurotransmission systems in Parkinson's disease.
- To explore the disturbance of these systems in PD pathophysiology.
- To discuss potential therapeutic applications targeting these neurotransmitter systems.
Main Methods:
- A comprehensive literature review was conducted.
- Databases searched included PubMed, Science Direct, EMBASE, and Web of Science.
- The review focused on English literature.
Main Results:
- PD affects multiple neurotransmitter systems, including glutamatergic, GABAergic, cholinergic, serotoninergic, and endocannabinoid systems.
- Disturbances in these systems contribute to the complex pathophysiology of PD.
- Understanding these systems offers insights into potential treatment strategies.
Conclusions:
- Neurotransmitter system dysregulation is integral to Parkinson's disease.
- Targeting both dopaminergic and non-dopaminergic pathways holds promise for PD treatment.
- Further research into network circuit disturbances is warranted.
More Related Videos
Related Concept Videos
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:37Neural Regulation
43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
01:29Excitatory and Inhibitory Effects of Neurotransmitters
14.0K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
14.0K
01:29Drugs Affecting Neurotransmitter Synthesis
2.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.4K
01:31Neurotransmitters
3.0K
Neurotransmitters are essential chemical messengers within the nervous system, facilitating the communication between neurons. These chemical messengers, varying in function and effect, are critical for sustaining various aspects of neurological health and emotional well-being.
3.0K